A real-world pharmacovigilance study of omalizumab using disproportionality analysis in the FDA adverse drug events reporting system database

Y Yongfu Song Z Zhuang Wang (State Key Laboratory of Photoelectric Conversion and Utilization of Solar Energy, Qingdao New Energy Shandong Laboratory, Qingdao Institute of Bioenergy and Bioprocess Technology) N Na Wang X Xiaofei Xie T Tieshi Zhu Y Yongji Wang (School of Chemistry and Chemical Engineering of Shihezi University)

Article Details

Volume / Issue Vol. 15, Issue 1
Published March 07, 2025
ISSN 2045-2322
Publisher Nature Portfolio

Journal Info

Scientific Reports

Nature Portfolio

ISSN: 2045-2322 Open Access Life Sciences

Authors (6)

Y

Yongfu Song

Z

Zhuang Wang

State Key Laboratory of Photoelectric Conversion and Utilization of Solar Energy, Qingdao New Energy Shandong Laboratory, Qingdao Institute of Bioenergy and Bioprocess Technology

N

Na Wang

X

Xiaofei Xie

T

Tieshi Zhu

Y

Yongji Wang

School of Chemistry and Chemical Engineering of Shihezi University